The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study
Authors:
- BETA study groupBGBETA study group
- Ji Sung YoonJYJi Sung Yoon
- Kyu Chang WonKWKyu Chang Won
- 21 January 2014
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 51 (2) , 277-285
Abstract
The aim of present study is to assess whether if basal insulin, glargine, could improve insulin secretory function of β-cells compared with glimepiride when metformin alone was failed. This was an open-label and multi-center study for 52 weeks in Korean patients with uncontrolled type 2 diabetes by metformin monotherapy. Subjects were randomized to glargine or glimepiride groups (n = 38 vs. 36, respectively). The primary endpoint was to compare changes in c-peptide via glucagon test after 48 weeks. Glycemic efficacy and safety endpoints (glycated hemoglobin (HbA1c), HOMA-B, fasting plasma glucose (FPG), lipid profiles, and hypoglycemic events) were also checked. The mean disease duration of all subjects was 88.2 months. Changes in C-peptide was no significant different between groups (P = 0.73), even though insulin secretion was not worsened in both groups at the endpoint. Glargine was not superior to glimepiride in other β-cell function indexes such as HOMA-B (P = 0.28). HbA1c and FPG reduced significantly in each groups but not different between two groups. Although, severe hypoglycemia did not occur, symptomatic hypoglycemia was more frequent in glimepiride group (P = 0.01). Insulin glargine was as effective as glimepiride in controlling hyperglycemia and maintaining β-cell function in Korean patients with type 2 diabetes during 48 weeks study period, after failure of metformin monotherapy. Hypoglycemic profile was favorable in the insulin glargine group and less weight gain was observed in the glimepiride group. Our results suggest that glargine and glimepiride can be considered after failure of metformin monotherapy.Keywords
This publication has 38 references indexed in Scilit:
- Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetesActa Diabetologica, 2013
- The Efficacy of Vildagliptin in Korean Patients with Type 2 DiabetesDiabetes & Metabolism Journal, 2013
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Associations among Body Mass Index, Insulin Resistance, and Pancreatic β-Cell Function in Korean Patients with New-Onset Type 2 DiabetesThe Korean Journal of Internal Medicine, 2012
- Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 DiabetesDiabetes Care, 2011
- The Changes in Early Phase Insulin Secretion in Newly Diagnosed, Drug Naive Korean Prediabetes SubjectsKorean Diabetes Journal, 2010
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐upDiabetes, Obesity and Metabolism, 2007
- Metabolic memory in diabetes-focus on insulinDiabetes/Metabolism Research and Reviews, 2004
- Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F CellsBiochemical and Biophysical Research Communications, 2000